Immucell (ICCC) Current Assets (2010 - 2026)

Immucell (ICCC) has reported Current Assets for 17 consecutive years, with $21.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 23.01% year-over-year to $21.1 million; the trailing twelve-month figure through Jun 2026 stood at $21.1 million (up 23.01% YoY), and the FY2025 full-year result was $16.9 million, up 12.64% from the prior year.
• Current Assets improved to $21.1 million in Q2 2026 per ICCC's latest filing, from $16.9 million in the prior quarter.
• Across five years, Current Assets topped out at $21.1 million in Q2 2026 and bottomed at $10.8 million in Q2 2024.
• Historically, Current Assets has averaged $14.8 million across 5 years, with a median of $15.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Assets tumbled 36.83% in 2023, then soared 58.76% in 2025.
• Over 5 years, Current Assets stood at $14.0 million in 2022, then declined by 18.04% to $11.5 million in 2023, then jumped by 31.15% to $15.0 million in 2024, then increased by 12.64% to $16.9 million in 2025, then grew by 24.4% to $21.1 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $21.1 million, $16.9 million, and $16.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.